

Tuberculosis profile: Georgia

Population 2019: 4 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	3 000 (2 500-3 500)	74 (62-87)
HIV-positive TB incidence	53 (35-74)	1.3 (0.88-1.9)
MDR/RR-TB incidence**	530 (420-650)	13 (10-16)
HIV-negative TB mortality	150 (140-170)	3.8 (3.5-4.2)
HIV-positive TB mortality	14 (9-20)	0.34 (0.22-0.5)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	12% (10-14)
Previously treated cases	32% (28-37)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	73% (62-87)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	6% (5-7)

TB case notifications, 2019

Total new and relapse	2 169
- % tested with rapid diagnostics at time of diagnosis	84%
- % with known HIV status	85%
- % pulmonary	81%
- % bacteriologically confirmed ^	91%
- % children aged 0-14 years	3%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	30%
- % men	67%
Total cases notified	2 451

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	33	1.8%
- on antiretroviral therapy	33	100%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	99%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	93%
Laboratory-confirmed cases - MDR/RR-TB ^^	319
Patients started on treatment - MDR/RR-TB ^^	301
Laboratory-confirmed cases - XDR-TB ^^	31
Patients started on treatment - XDR-TB ^^	24
MDR/RR-TB cases tested for resistance to any fluoroquinolone	242

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	84%	2 071
Previously treated cases, excluding relapse, registered in 2018	62%	189
HIV-positive TB cases registered in 2018	68%	31
MDR/RR-TB cases started on second-line treatment in 2017	64%	316
XDR-TB cases started on second-line treatment in 2017	60%	47

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	
---	--



Treatment success rate



Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 20% (18-22)

TB financing

National TB budget, 2020 (US\$ millions)	12
- Funding source, domestic	48%
- Funding source, international	40%
- unfunded	12%

* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-21 by the World Health Organization (<https://www.who.int/tb/data/>)